Appendix FNational Biospecimen Network Blueprint Design Team and Advisors Meeting Participant List
July 28–29, 2003
Hyatt Regency Bethesda • One Bethesda Metro Center • Bethesda, MD
Anna D. Barker, Ph.D., National Cancer Institute and NDC Research Team Chair
Jeffrey Trent, Ph.D., Translational Genomics Research Institute (TGen)
and TAWG Co-Director
Paula Kim, Pancreatic Cancer Action Network and TAWG Co-Director
Roger Aamodt, Ph.D., National Cancer Institute
Michael E. Berens, Ph.D., The International Genomics Consortium
Kerry L. Blanchard, M.D., Ph.D., Eli Lilly and Company
Alan Buckler, Ph.D., Ardais Corporation
Kenneth H. Buetow, Ph.D., National Cancer Institute
Robert L. Cohen, M.D., Genentech
Carolyn Compton, M.D., Ph.D., McGill University
Peter Covitz, Ph.D., National Cancer Institute
Dan Crichton, National Aeronautics and Space Administration
Mary E. Edgerton, M.D., Ph.D., Vanderbilt University Medical Center
Elisa Eiseman, Ph.D., RAND Corporation
William Grizzle, M.D., Ph.D., University of Alabama at Birmingham
Rina Hakimian, J.D., M.P.H., Association of American Medical Colleges
Stanley R. Hamilton, M.D., University of Texas M.D. Anderson Cancer Center
Stephen Hewitt, M.D., Ph.D., National Cancer Institute
Arthur L. Holden, M.B.A., Ph.D., First Genetic Trust – SNP Consortium
Valerie Hurt, J.D., National Institutes of Health
Julie Kaneshiro, DHHS Office for Human Research Protections
Kirstine Knox, Ph.D., National Translational Cancer Research Network
Thane Kreiner, Ph.D., Affymetrix, Inc.
Annette Levey, J.D., National Institutes of Health
Amy McGuire, Foundation for the National Institutes of Health
John D. Potter, M.D., Ph.D., Fred Hutchinson Cancer Research Center
Wendy R. Sanhai, Ph.D., Foundation for the National Institutes of Health
Howard Schulman, Ph.D., SurroMed, Inc.
Mary Lou Smith, J.D., Research Advocacy Network
Janet Warrington, Ph.D., Affymetrix, Inc.
Victor Weedn, M.D., J.D., Carnegie Mellon University
|
